Cargando…

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

BACKGROUND: Patients with advanced renal cell carcinoma with sarcomatoid features (sRCC) have a poor prognosis and limited therapeutic options. First-line nivolumab plus ipilimumab (NIVO+IPI) provided efficacy benefits over sunitinib (SUN) in patients with intermediate/poor-risk sRCC at 42 months mi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rini, Brian I, Signoretti, Sabina, Choueiri, Toni K, McDermott, David F, Motzer, Robert J, George, Saby, Powles, Thomas, Donskov, Frede, Tykodi, Scott S, Pal, Sumanta K, Gupta, Saurabh, Lee, Chung-Wei, Jiang, Ruiyun, Tannir, Nizar M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791431/ https://www.ncbi.nlm.nih.gov/pubmed/36549781 http://dx.doi.org/10.1136/jitc-2022-005445

Ejemplares similares

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
por: Motzer, Robert J, et al.
Publicado: (2022)

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
por: Motzer, Robert J, et al.
Publicado: (2021)

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2022)

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
por: Albiges, Laurence, et al.
Publicado: (2020)

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
por: Choueiri, Toni K, et al.
Publicado: (2022)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
por: Atkins, Michael B, et al.
Publicado: (2023)

Soluble PD-L1 as an early marker of progressive disease on nivolumab
por: Mahoney, Kathleen M, et al.
Publicado: (2022)

Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab
por: Brown, Landon C., et al.
Publicado: (2021)

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
por: Regan, Meredith M., et al.
Publicado: (2021)

Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab
por: McQuade, Jennifer L., et al.
Publicado: (2022)

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2021)

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2021)

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
por: Najjar, Yana G, et al.
Publicado: (2020)

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
por: Wong, Jeffrey Sum Lung, et al.
Publicado: (2021)

Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
por: He, Jie, et al.
Publicado: (2023)

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial
por: Tykodi, Scott S, et al.
Publicado: (2022)

P060: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment
por: Fedorova, Liudmila, et al.
Publicado: (2022)

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
por: Koguchi, Yoshinobu, et al.
Publicado: (2021)

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients
por: Donskov, Frede, et al.
Publicado: (2015)

Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial
por: Klein, Oliver, et al.
Publicado: (2021)

Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
por: Khushalani, Nikhil I, et al.
Publicado: (2022)

Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck
por: Johnson, Jennifer M, et al.
Publicado: (2023)

Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up
por: Tomita, Yoshihiko, et al.
Publicado: (2019)

IMMU-09. NIVOLUMAB THERAPY FOR A PEDIATRIC-ONSET PRIMARY INTRACRANIAL MELANOMA
por: Oba, Utako, et al.
Publicado: (2020)

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
por: Larkin, James, et al.
Publicado: (2023)

Renal cell carcinoma with non-clear cell histology or sarcomatoid differentiation: recent insight in an unmet clinical need
por: Donskov, Frede
Publicado: (2021)

Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial
por: Choueiri, T.K., et al.
Publicado: (2021)

Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial
por: Martin-Broto, Javier, et al.
Publicado: (2020)

Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG
por: Glutsch, Valerie, et al.
Publicado: (2022)

Case Report: Response to ipilimumab and nivolumab in a patient with adrenocortical carcinoma
por: Charles, Rebecca, et al.
Publicado: (2023)

Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody
por: Bilen, Mehmet Asim, et al.
Publicado: (2016)

Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
por: Amaral, Teresa, et al.
Publicado: (2020)

Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials
por: Kang, Yoon-Koo, et al.
Publicado: (2022)

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
por: Lau, Peter Kar Han, et al.
Publicado: (2021)

P062: The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma
por: Fedorova, Liudmila, et al.
Publicado: (2022)

Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab
por: Veatch, Joshua R, et al.
Publicado: (2020)

Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses
por: Friedman, Claire F, et al.
Publicado: (2022)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
por: Ross-Macdonald, Petra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ugkse025brira4l6okhdetqcqh